In 2022, approximately 704.2 males per 100,000 and 562 females per 100,000 in England were newly diagnosed with cancer, excluding non-melanoma skin cancer. Overall, the diagnosis rate for both genders showed a slight increasing trend over the years. This statistic shows the rate of newly diagnosed cases of cancer per 100,000 population in England from 2019 to 2022, by gender.

In 2019, approximately ** men and ** women per 100,000 population died from lung cancer in England. The North East of England had the highest mortality from lung cancer for both genders with a rate of approximately ** men and ** women per 100,000 population.

Cancer diagnoses and age-standardised incidence rates for all types of cancer by age and sex including breast, prostate, lung and colorectal cancer.

This publication reports on newly diagnosed cancers registered in England in addition to cancer deaths registered in England during 2020. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document.

In the period 2017 to 2019, the mortality rate from kidney cancer in the United Kingdom was **** deaths per 100,000 men and *** deaths per 100,000 women. Across the overall provided time interval the mortality rate from kidney cancer has increased in the UK, although the rate has been fairly stable in recent years.

One-year and five-year net survival for adults (15-99) in England diagnosed with one of 29 common cancers, by age and sex.

Age-standardised rate of mortality from oral cancer (ICD-10 codes C00-C14) in persons of all ages and sexes per 100,000 population.RationaleOver the last decade in the UK (between 2003-2005 and 2012-2014), oral cancer mortality rates have increased by 20% for males and 19% for females1Five year survival rates are 56%. Most oral cancers are triggered by tobacco and alcohol, which together account for 75% of cases2. Cigarette smoking is associated with an increased risk of the more common forms of oral cancer. The risk among cigarette smokers is estimated to be 10 times that for non-smokers. More intense use of tobacco increases the risk, while ceasing to smoke for 10 years or more reduces it to almost the same as that of non-smokers3. Oral cancer mortality rates can be used in conjunction with registration data to inform service planning as well as comparing survival rates across areas of England to assess the impact of public health prevention policies such as smoking cessation.References:(1) Cancer Research Campaign. Cancer Statistics: Oral – UK. London: CRC, 2000.(2) Blot WJ, McLaughlin JK, Winn DM et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988; 48: 3282-7. (3) La Vecchia C, Tavani A, Franceschi S et al. Epidemiology and prevention of oral cancer. Oral Oncology 1997; 33: 302-12.Definition of numeratorAll cancer mortality for lip, oral cavity and pharynx (ICD-10 C00-C14) in the respective calendar years aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+). This does not include secondary cancers or recurrences. Data are reported according to the calendar year in which the cancer was diagnosed.Counts of deaths for years up to and including 2019 have been adjusted where needed to take account of the MUSE ICD-10 coding change introduced in 2020. Detailed guidance on the MUSE implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/causeofdeathcodinginmortalitystatisticssoftwarechanges/january2020Counts of deaths for years up to and including 2013 have been double adjusted by applying comparability ratios from both the IRIS coding change and the MUSE coding change where needed to take account of both the MUSE ICD-10 coding change and the IRIS ICD-10 coding change introduced in 2014. The detailed guidance on the IRIS implementation is available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/impactoftheimplementationofirissoftwareforicd10causeofdeathcodingonmortalitystatisticsenglandandwales/2014-08-08Counts of deaths for years up to and including 2010 have been triple adjusted by applying comparability ratios from the 2011 coding change, the IRIS coding change and the MUSE coding change where needed to take account of the MUSE ICD-10 coding change, the IRIS ICD-10 coding change and the ICD-10 coding change introduced in 2011. The detailed guidance on the 2011 implementation is available at https://webarchive.nationalarchives.gov.uk/ukgwa/20160108084125/http://www.ons.gov.uk/ons/guide-method/classifications/international-standard-classifications/icd-10-for-mortality/comparability-ratios/index.htmlDefinition of denominatorPopulation-years (aggregated populations for the three years) for people of all ages, aggregated into quinary age bands (0-4, 5-9, …, 85-89, 90+)

In the period 2017 to 2019, the mortality rate from melanoma skin cancer in the United Kingdom was *** deaths per 100,000 for men and *** deaths per 100,000 for women. Across the overall provided time interval the mortality rate from skin cancer has increased significantly in the UK, although there has been a slight decline since 2012-2014.

This release summarises the survival of adults diagnosed with cancer in England between 2015 and 2019 and followed to 2020, and children diagnosed with cancer in England between 2002 and 2019 and followed to 2020. Adult cancer survival estimates are presented by age, deprivation, gender, stage at diagnosis and geography. Update 8th June 2022: We have now published an additional ODS data file ‘Cancer Survival in England Back Series, cancers diagnosed from 2006 to 2018: Adults’. This publication presents a back series of 1- to 5-year net survival for adults (15 to 99 years) diagnosed with cancer between 2006 to 2018 (5-year rolling cohorts). This back series was completed due to a change in methodology in the most recent publication (Cancers diagnosed between 2015 and 2019) to allow for comparison of net survival estimates over time.

In 2018/19, the mortality rate from non-melanoma skin cancer in the United Kingdom was *** deaths per 100 thousand for men and *** deaths per 100 thousand for women. Across the provided time interval the mortality rate from non-melanoma skin cancer has decreased for women, while the rate for men has experienced more fluctuations but was a higher rate at the start and the end of the provided time interval.

Directly age and sex standardised mortality rate from Cancer for people aged under 75 in the respective calendar year per 100,000 registered patients March 2020: In addition to the changes in March 2019, the indicator production process has been fully automated. As a result there are two changes to this publication: 1) Data in this file are published from 2016 only; all data is based on the most recent methodology and comparable across years. For the historic time series of this indicator please refer to the zip files in the March 2019 publication: https://digital.nhs.uk/data-and-information/publications/clinical-indicators/ccg-outcomes-indicator-set/archive/ccg-outcomes-indicator-set---march-2019 2) Data are run against the CCG configuration at the time of processing; the 2016 and 2017 data points have been restated based on the new automated process. As of the March 2019 release the processing of the Primary Care Mortality Database (PCMD) and the standard population used to calculate the indicator for new data periods changed; this file now contains only those data periods processed under the new method. For the historic time series of this indicator please refer to the zip files in the March 2019 publication referenced above. Legacy unique identifier: P01808

Directly age-standardised registration rate for oral cancer (ICD-10 C00-C14), in persons of all ages, per 100,000 2013 European Standard PopulationRationaleTobacco is a known risk factor for oral cancers (1). In England, 65% of hospital admissions (2014–15) for oral cancer and 64 % of deaths (2014) due to oral cancer were attributed to smoking (2). Oral cancer registration is therefore a direct measure of smoking-related harm. Given the high proportion of these registrations that are due to smoking, a reduction in the prevalence of smoking would reduce the incidence of oral cancer.Towards a Smokefree Generation: A Tobacco Control Plan for England states that tobacco use remains one of our most significant public health challenges and that smoking is the single biggest cause of inequalities in death rates between the richest and poorest in our communities (3).In January 2012 the Public Health Outcomes Framework was published, then updated in 2016. Smoking and smoking related death plays a key role in two of the four domains: Health Improvement and Preventing premature mortality (4).References:(1) GBD 2013 Risk Factors Collaborators. Global, regional and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risk factors in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet 2015; 386:10010 2287–2323. (2) Statistics on smoking, England 2016, May 2016; http://content.digital.nhs.uk/catalogue/PUB20781 (3) Towards a Smokefree Generation: A Tobacco Control Plan for England, July 2017 https://www.gov.uk/government/publications/towards-a-smoke-free-generation-tobacco-control-plan-for-england (4) Public Health Outcomes Framework 2016 to 2019, August 2016; https://www.gov.uk/government/publications/public-health-outcomes-framework-2016-to-2019 Definition of numeratorCancer registrations for oral cancer (ICD-10, C00-C14) in the calendar years 2007-09 to 2017-2019. The National Cancer Registration and Analysis Service collects data relating to each new diagnosis of cancer that occurs in England. This does not include secondary cancers. Data are reported according to the calendar year in which the cancer was diagnosed.Definition of denominatorPopulation-years (ONS mid-year population estimates aggregated for the respective years) for people of all ages, aggregated into quinary age bands (0-4, 5-9,…, 85-89, 90+).CaveatsReviews of the quality of UK cancer registry data 1, 2 have concluded that registrations are largely complete, accurate and reliable. The data on cancer registration ‘quality indicators’ (mortality to incidence ratios, zero survival cases and unspecified site) demonstrate that although there is some variability, overall ascertainment and reliability is good. However cancer registrations are continuously being updated, so the number of registrations for each year may not be complete, as there is a small but steady stream of late registrations, some of which only come to light through death certification.1. Huggett C (1995). Review of the Quality and Comparability of Data held by Regional Cancer Registries. Bristol: Bristol Cancer Epidemiology Unit incorporating the South West Cancer Registry. 2. Seddon DJ, Williams EMI (1997). Data quality in population based cancer registration. British Journal of Cancer 76: 667-674.The data presented here replace versions previously published. Population data and the European Standard Population have been revised. ONS have provided an explanation of the change in standard population (available at http://www.ons.gov.uk/ons/guide-method/user-guidance/health-and-life-events/revised-european-standard-population-2013--2013-esp-/index.html )

Smoothed life tables for use in cancer survival, by sex, index of multiple deprivation, age and region of England.

This statistic displays the share of information provided about operations for cancer in the United Kingdom in 2019. The majority of respondents, 95.4 percent, said they had all the information they needed before their operation.

The Get Data Out programme from the National Disease Registration Service publishes detailed statistics about small groups of cancer patients in a way that ensures patient anonymity is maintained. The Get Data Out programme currently covers 15 cancer sites. This data release updates the incidence data for all 15 sites to cover 2013-2020 (previous data covered 2013-2019) and also adds new cancer sites ‘Liver and biliary tract’, 'Haematological malignancies' and 'Haematological malignancy transformations'. The 18 cancer sites now covered by Get Data Out are: ‘Bladder, Urethra, Renal Pelvis and Ureter’, ‘Bone cancer’, ‘Brain, meningeal and other primary CNS tumours’, ‘Eye cancer’, 'Haematological malignancies', 'Haematological malignancy transformations', ‘Head and neck’, ‘Kaposi sarcoma’, ‘Kidney’, 'Liver and Biliary tract', ‘Oesophageal and Stomach’, ‘Ovary, fallopian tube and primary peritoneal carcinomas’, ‘Pancreas’, ‘Prostate’, ‘Sarcoma’, ‘Skin tumours’, ‘Soft tissue and peripheral nerve cancer’, ‘Testicular tumours including post-pubertal teratomas’. Anonymisation standards are designed into the data by aggregation at the outset. Patients diagnosed with a certain type of tumour are divided into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These groups are aimed to be clinically meaningful and differ across cancer sites. For each group of patients, Get Data Out routinely publish statistics about incidence, routes to diagnosis, treatments and survival. All releases and documentation are available on the Get Data Out main technical page. Before using the data, we recommend that you read the guide for first time users. The data is available in an open format for anyone to access and use. We hope that by releasing anonymous detailed data like this we can help researchers, the public and patients themselves discover more about cancer. If you have feedback or any other queries about Get Data Out, please email us at NDRSenquires@nhs.net and mention 'Get Data Out' in your email.

This file contains the digital vector boundaries for Cancer Alliances, in England, as at 1 July 2019.

The boundaries available are:(BFE) Full resolution - extent of the realm (usually this is the Mean Low Water mark but in some cases boundaries

extend beyond this to include off shore islands).Contains both Ordnance Survey and ONS Intellectual Property Rights. Units for the following fields:st_length = metresst area = metres²Download File Sizes

Full resolution - extent of the realm (8.2 MB) REST URL of ArcGIS for INSPIRE View Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BFE/MapServer/exts/InspireView REST URL of ArcGIS for INSPIRE Feature Download Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BFE/MapServer/exts/InspireFeatureDownload REST URL of Feature Access Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BFE/FeatureServer

This file contains the digital vector boundaries for Cancer Alliances, in England, as at 1 July 2019.

The boundaries available are:(BUC) Ultra generalised (500m) - clipped to the coastline (Mean High Water mark). Contains both Ordnance Survey and ONS Intellectual Property Rights. Units for the following fields:st_length = metresst area = metres²Download File Sizes Ultra generalised (500m) - clipped to the coastline (90 KB). REST URL of ArcGIS for INSPIRE View Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BUC/MapServer/exts/InspireView REST URL of ArcGIS for INSPIRE Feature Download Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BUC/MapServer/exts/InspireFeatureDownload REST URL of Feature Access Service – https://ons-inspire.esriuk.com/arcgis/rest/services/Health_Boundaries/Cancer_Alliances_July_2019_EN_BUC/FeatureServer